August Von Wassermann
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Pre-Antibiotic Therapy of Syphilis Charles T
University of Kentucky UKnowledge Microbiology, Immunology, and Molecular Microbiology, Immunology, and Molecular Genetics Faculty Publications Genetics 2016 Pre-Antibiotic Therapy of Syphilis Charles T. Ambrose University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/microbio_facpub Part of the Medical Immunology Commons Repository Citation Ambrose, Charles T., "Pre-Antibiotic Therapy of Syphilis" (2016). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 83. https://uknowledge.uky.edu/microbio_facpub/83 This Article is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics at UKnowledge. It has been accepted for inclusion in Microbiology, Immunology, and Molecular Genetics Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Pre-Antibiotic Therapy of Syphilis Notes/Citation Information Published in NESSA Journal of Infectious Diseases and Immunology, v. 1, issue 1, p. 1-20. © 2016 C.T. Ambrose This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This article is available at UKnowledge: https://uknowledge.uky.edu/microbio_facpub/83 Journal of Infectious Diseases and Immunology Volume 1| Issue 1 Review Article Open Access PRE-ANTIBIOTICTHERAPY OF SYPHILIS C.T. Ambrose, M.D1* 1Department of Microbiology, College of Medicine, University of Kentucky *Corresponding author: C.T. Ambrose, M.D, College of Medicine, University of Kentucky Department of Microbiology, E-mail: [email protected] Citation: C.T. -
Wassermann, August Paul Von (1866-1925)
University of Calgary PRISM: University of Calgary's Digital Repository Cumming School of Medicine Cumming School of Medicine Research & Publications 2007 Wassermann, August Paul von (1866-1925) Stahnisch, Frank W. Greenwood Stahnisch, F.: ,,Wassermann, August Paul von (1866-1925)". In: Dictionary of Medical Biography (DMB). W. F. Bynum and Helen Bynum (eds.). Westport, CO, London: Greenwood 2007, Vol. 5, p. 1290f. http://hdl.handle.net/1880/48269 Other Downloaded from PRISM: https://prism.ucalgary.ca WASSERMANN, AUGUST PAUL VON (b. Bamberg, Germany, 21 February 1866; d. Berlin, Germany, 16 March 1925), clinical chemistry, serology. Wassermann was born in Bamberg and began to study medicine in the nearby university town of Erlangen, before heading to Munich, Vienna, and Strassburg. In 1888 Wassermann graduated MD at the German university of Strassburg and began to work as research assistant to Robert Koch in the Institute for Infectious Diseases of Friedrich- Wilhelms-University of Berlin. Here he was introduced to the methods of laboratory experimentation and to Koch's concept of the relevance of bacteriology for clinical medi• cine. At the Institute for Infectious Diseases, Wassermann worked on immunity phenomena related to cholera infec• tion and tried to develop antitoxins against diphtheria. As a result of these experimental investigations, he received the 'venia legendi' for hygiene in 1901. Following Paul Ehrlich's advice, Wassermann began to study the binding of toxin and antitoxin in the blood. He then investigated the differing reactions of blood groups in response to various precipitat• ing blood sera. In 1902 Wassermann was made 'Extraordi- narius' at the institute and in 1906 received the directorship of the division of experimental therapy and biochemistry. -
Tick-Borne Relapsing Fever, Malta Fever, Glanders, SARS
ARTICLE IN PRESS International Journal of Medical Microbiology 296 (2006) 1–4 www.elsevier.de/ijmm EDITORIAL Killed in action: Microbiologists and clinicians as victims of their occupation Part 4: Tick-borne Relapsing Fever, Malta Fever, Glanders, SARS Tick-borne Relapsing Fever money at the disposal of this expedition. The researchers left Liverpool on September 23, and reached the Stanley A microbiologist and pathologist, who was engaged Falls at the end of the year. Dutton’s special interest was in research on African Tick-borne Relapsing Fever, directed to tick-borne relapsing fever of the Central Joseph Everett Dutton (Fig. 1), became a victim of this African type. He was able to infect monkeys by the bites disease. He was born on 9th of September 1874 in of spirochaete-carrying soft ticks, Ornithodorus mouba- Higher Bebington, Cheshire, as the fifth son of the ta. What he did not know, Philip Ross and Milne made chemist John Dutton, was educated from 1888 to 1892 the same experiment a few weeks before in Uganda. in the King’s School of Chester, and entered the Dutton found also that Borrelia duttoni could pass into Liverpool Medical School and the Royal Infirmary in the eggs and larvae, and so confer infective potential on the same town. In 1897 he was graduated and was the tick of the succeeding generation (Manson-Bahr, appointed to the George Holt Fellowship in Pathology. 1951). Robert Koch (1906), who had no information One year in the Departments of Surgery followed. He about these results, found while he was in East Africa in undertook his first scientific expedition in 1900 as a 1905 that this transmission is possible up to the third member of the third expedition of the Liverpool School generation. -
THE BLUE CARD CALENDAR 5 7 8 1 the BLUE CARD Is a Charitable Organization That Has Been Aiding Holocaust Survivors Since 1934
THE BLUE CARD CALENDAR 5 7 8 1 THE BLUE CARD is a charitable organization that has been aiding Holocaust survivors since 1934. It is dedicated to the support of European Jewish survivors and their descendants in this country, who still suffer from the aftereffects of Nazi persecution, are sick or emotionally unstable, have been unable to achieve economic independence, or have lost it through sickness or old age; in many cases the Holocaust has deprived them of family. The Blue Card’s activities aren’t duplicated by any other Jewish welfare agencies. During the year 2019, The Blue Card distributed nearly $2.7 million. This brings the grant total since The Blue Card’s inception to over $40 million. THE BLUE CARD continues to receive four-star ratings from Charity Navigator, a distinction awarded to only four percent of all charities. The Blue Card is Better Business Bureau (BBB) accredited. THE BLUE CARD mirrors the social conscience of our community. We hope it will be important to you, and that you will remember it in your last will. Your contribution is fully tax deductible. THE BLUE CARD has been publishing this calendar for its friends and friends-to-be for more than 50 years in order to remind them, throughout the year, that there is an organization which is always ready to render assistance to our neediest. PLEASE SEE the inside back cover of this calendar for more information about The Blue Card. A copy of the most recent financial report may be obtained from The Blue Card, Inc., 171 Madison Ave. -
Annette Hinz-Wessels Das Robert Koch-Institut Im Nationalsozialismus Das Robert Koch-Institut (Um 1900) Annette Hinz-Wessels
Annette Hinz-Wessels Das Robert Koch-Institut im Nationalsozialismus Das Robert Koch-Institut (um 1900) Annette Hinz-Wessels Das Robert Koch-Institut im Nationalsozialismus Kulturverlag Kadmos Berlin Titelseite oben: unter Verwendung des Fotos Reichsgesundheitsführer Leonardo Conti bei einer Institutsbesichtigung, 1.4.1942. Im Vordergrund Gerhard Rose. Titelseite unten: Robert Koch-Ehrung anlässlich seines 25. Todestages Bibliografi sche Information Der Deutschen Nationalbibliothek Die Deutsche Nationalbibliothek verzeichnet diese Publikation in der Deutschen Nationalbibliografi e; detaillierte bibliografi sche Daten sind im Internet über <http://dnb.d-nb.de> abrufbar Das Werk einschließlich aller seiner Teile ist urheberrechtlich geschützt. Jede Ver - wertung ist ohne Zustimmung des Verlages unzulässig. Das gilt insbesondere für Vervielfältigungen, Übersetzungen, Mikroverfi lmungen und die Einspeicherung und Verarbeitung in elektronischen Systemen. Copyright © 2012 (erste Aufl age 2008), Kulturverlag Kadmos Berlin. Wolfram Burckhardt Alle Rechte vorbehalten Internet: www.kv-kadmos.com Umschlaggestaltung: kaleidogramm, Berlin, Gestaltung und Satz: kaleidogramm, Berlin Druck: Booksfactory Printed in EU ISBN (10-stellig) 3-86599-167-X ISBN (13-stellig) 978-3-86599-167-6 Inhalt Vorwort von Volker Hess . 7 I. Historischer Überblick . 9 II. Vom »Institut für Infektionskrankheiten« zur »Reichsanstalt zur Bekämpfung der übertragbaren Krankheiten« – personeller Wandel und organisatorischer Umbau des Robert Koch-Instituts im »Dritten Reich« . 21 Personalentlassungen -
KARL FRIEDRICH MEYER May 19, 1884-April 27, 1974
NATIONAL ACADEMY OF SCIENCES K ARL FRIEDRICH M EYER 1884—1974 A Biographical Memoir by A L B E R T D . S A B IN Any opinions expressed in this memoir are those of the author(s) and do not necessarily reflect the views of the National Academy of Sciences. Biographical Memoir COPYRIGHT 1980 NATIONAL ACADEMY OF SCIENCES WASHINGTON D.C. KARL FRIEDRICH MEYER May 19, 1884-April 27, 1974 BY ALBERT D. SABIN* F MEYER (henceforth "KF," as he was affectionately called K by his colleagues) was an outstanding bacteriologist, experimental pathologist, virologist, epidemiologist, ecolo- gist, brilliant and inspiring teacher, and a prototype of the scientist in the service of society. In the tradition of Pasteur and Koch, his scientific studies invariably involved the acquisition of knowledge for the understanding and solution of important practical problems in the field of human and animal diseases. In 1951, when KF was sixty-seven years young, the American Public Health Association presented him a Lasker Award with the following citation that aptly expressed the esteem of his colleagues and summarized his major contributions to science and public health: Brilliant scientist, dynamic teacher, inspired humanitarian. His influ- ence now extends over two generations of students of medicine, biology, *In writing this biographical memoir, I tried whenever possible to let K. F. Meyer talk for himself in his own colorful, inimitable manner. I am indebted to the director of the Bancroft Library of the University of California, Berkeley, for permission to quote from Dr. Meyer's oral history memoir entitled Medical Research and Public Health (Berkeley: University of California, 1976), a transcript of a 1961-1962 unedited tape-recorded oral interview by Edna Tartaul Daniel, Regional Oral History Office, The Bancroft Library. -
Pharmaceutical Markets in the German Empire
www.ssoar.info Pharmaceutical markets in the German Empire: profits between risk, altruism and regulation Hüntelmann, Axel C. Veröffentlichungsversion / Published Version Zeitschriftenartikel / journal article Zur Verfügung gestellt in Kooperation mit / provided in cooperation with: GESIS - Leibniz-Institut für Sozialwissenschaften Empfohlene Zitierung / Suggested Citation: Hüntelmann, A. C. (2011). Pharmaceutical markets in the German Empire: profits between risk, altruism and regulation. Historical Social Research, 36(3), 182-201. https://doi.org/10.12759/hsr.36.2011.3.182-201 Nutzungsbedingungen: Terms of use: Dieser Text wird unter einer CC BY Lizenz (Namensnennung) zur This document is made available under a CC BY Licence Verfügung gestellt. Nähere Auskünfte zu den CC-Lizenzen finden (Attribution). For more Information see: Sie hier: https://creativecommons.org/licenses/by/4.0 https://creativecommons.org/licenses/by/4.0/deed.de Diese Version ist zitierbar unter / This version is citable under: https://nbn-resolving.org/urn:nbn:de:0168-ssoar-357599 Pharmaceutical Markets in the German Empire. Profits Between Risk, Altruism and Regulation Axel C. Hüntelmann Abstract: »Pharma-Märkte im Deutschen Kaiserreich. Profite zwischen Risi- ko, Altruismus und Regulierung«. For the first time in August 1894, phials of anti-diphtheria serum went on sale in German pharmacies. Anti-diphtheria se- rum was a major therapeutic innovation in the treatment of a terrible infectious disease. The anti-diphtheria serum also signalled the evolution of new regula- tory institutions, as well as new markets in industrially produced pharmaceu- tics. The new serum therapy offered not only a cure for diphtheria and other fatal infectious diseases, but also promised high profits for the manufacturers who could stabilize the production process. -
Jules Bordet (1870-1961): Pioneer of Immunology
Singapore Med J 2013; 54(9): 475-476 M edicine in S tamps doi:10.11622/smedj.2013166 Jules Bordet (1870-1961): Pioneer of immunology Jonathan Dworkin1, MD, Siang Yong Tan2, MD, JD t the time when Jules Bordet began his ground- THE TRANSFORMATION OF IMMUNOLOGY breaking experiments at the Pasteur Institute, the field Bordet began work at the Pasteur Institute in 1894, and of immunology was shrouded in pseudoscientific despite being part of Metchnikoff’s lab, he was more interested uncertainty. The lifting of this veil, through the in studying serum than white cells. The arrangement was Apersistent and patient process of experimentation, was Bordet’s an awkward one in which Bordet was compelled to put into great contribution to medicine in the 20th century. writing his research findings regarding the role of phagocytes, although in reality, his work had little to do with phagocytosis. BACKGROUND Jules Bordet was born in 1870 in Bordet possessed a reserved temperament and shunned the Soignies, a small town in Belgium. In 1874, his family moved to cult of personality that then existed around the brilliant but Brussels, and he attended a primary school in the Ecole unstable Metchnikoff. Given the contrast with his fiery Russian Moyenne, where his father taught. In secondary school, Bordet mentor, it was no surprise that Bordet evolved into a careful became interested in chemistry, and at the age of sixteen, he scientist, skeptical of broad principles derived from scant enrolled into medical school at the Free University of Brussels. data and content to draw conclusions on as narrow a basis as His early promise as a researcher earned him a scholarship the facts supported. -
Download Launchpack
Britannica LaunchPacks | The Treatment and Prevention of Disease The Treatment and Prevention of Disease For Grades 6-8 This Pack contains: 5 ARTICLES 4 IMAGES 2 VIDEOS © 2020 Encyclopædia Britannica, Inc. 1 of 61 Britannica LaunchPacks | The Treatment and Prevention of Disease antibiotic Certain medicinal substances have the power to destroy or check the growth of infectious organisms in the body. The organisms can be bacteria, viruses, fungi, or the minuscule animals called protozoa. A particular group of these agents is made up of drugs called antibiotics, from the Greek anti (“against”) and bios (“life”). Some antibiotics are produced from living organisms such as bacteria, fungi, and molds. Others are wholly or in part synthetic—that is, produced artificially. Penicillin is perhaps the best known antibiotic. Its discovery and later development has enabled the medical profession to treat effectively many infectious diseases, including some that were once life-threatening. Antibiotics have revolutionized the treatment of bacterial infections in humans and other animals. They are, however, ineffective against viruses. Penicillium mold is grown in a lab. The mold is the source of penicillin, one of the first and most… Catolla—iStock/Thinkstock Learn about antibiotics. © Open University Antibiosis The general relationship between an antibiotic and an infectious organism is one of antibiosis. This word refers to an association of two organisms in which one is harmed or killed by the other. The relationship between human beings and disease-causing germs is one of antibiosis. If a person is affected by germs, he is the injured organism; if the germ attack is repelled by the body’s defenses, the germs are the injured organisms. -
Vol. 23, No. 2, 2019
The Publication on AIDS Vaccine Research WWW.IAVIREPORT.ORG | VOLUME 23, ISSUE 2 | DECEMBER 2019 A new viral vaccine The history of A new efficacy trial of vector has broad vaccination: adapting the mosaic HIV vaccine potential to the times candidate FROM THE EDITOR “It was the best of times, it was the worst of times…” from Janssen Vaccines & Prevention, part of the Jans- So begins Charles Dickens’s famous historical novel A sen Pharmaceutical Companies of Johnson & Johnson, Tale of Two Cities, published in 1859. Dickens was together with a consortium of public partners, began describing the years leading up to the French their second, and largest, efficacy study (named Revolution, yet it is an oddly apt description of the Mosaico) of Janssen’s mosaic-based HIV vaccine candi- current state of the vaccine field. date (see page 16). This October, the first Ebola vaccine was approved by Based on this, one might think it was the best of times. the European Medicines Agency. This is by all accounts But amidst all this progress, global cases of measles are an important milestone in battling outbreaks of a lethal on the rise, a disease for which a highly effective vaccine infectious disease that most often affects people in devel- has been available for more than 50 years. Last year oping countries. This vaccine, known as Ervebo, was more than 140,000 people worldwide died of measles, rapidly developed in 2014 during the deadliest outbreak most of them children under five years old, and 100 mil- of Ebola in history. It is estimated to be 97.5% effective. -
Albert L. Neisser (1855-1916), Microbiologist and Venereologist
Reprinted from www.antimicrobe.org Page 1 of 7 Albert L. Neisser (1855-1916), Microbiologist and Venereologist Thomas G. Benedek Albert Ludwig Neisser* is remembered mainly as the discoverer of the etiologic agent of gonorrhea and because he is memorialized eponymically with the bacterial genus to which it belongs. The generic name “Neisseria” was already proposed in 1885 by V. Trevisan, an Italian bacteriologist (1), but it was not adopted generally until the 1930s. Thus, for example, Neisseria meningitides, first cultured by Anton Weichselbaum (1845-1920, Vienna) in 1887, for long remained Diplococcus interellularis meningitides. Not only are the circumstances of Neisser’s professional development of interest, but his scientific career was more complex than a single important discovery. He was born Jan. 22, 1855 in a small Prussian town near the university city of Breslau. His father, Moritz Neisser, was a physician who was widowed during Albert’s infancy and he was raised largely by his stepmother. After attending a local elementary school, he attended Gymnasium in Breslau. Paul Ehrlich (1854-1915) was a classmate, beginning a life-long relationship. Between 1872 and 1877 he attended the University of Breslau, with some time also at the University of Erlangen (Nurnberg). He obtained his medical degree and license in 1877. Neisser wanted to remain in Breslau and, because the residency that he sought in internal medicine was not available, he accepted a residency in dermatology-venereology. At least the departments of pathology and dermatology lacked the prevailing anti- semitism. The latter department was already highly regarded in 1878, when it was chaired by Oscar Simon (1845-1882). -
Cent Ans D'un Prix Nobel Jules Bordet, Un Pastorien À L'ulb
Cent ans d’un prix Nobel Jules Bordet, ULB CULTURE • EXPOSITIONS • CULTURE ULB un pastorien à l’ULB Voyage au coeur de l’immunité Guide du visiteur LES 100 ANS Une exposition conçue et réalisée par D’UN NOBEL l’Université libre de Bruxelles JULES BORDET, UN PASTORIEN A L’ULB VOYAGE AU COEUR DE L’IMMUNITE Commissaire scientifique : Jean-Louis Vanherweghem, Professeur Honoraire, ULB Conception muséographique : Nathalie Levy Recherches et iconographie : Valentine Pigeolet Participation aux nocturnes des musées bruxellois les musées de l’ULB brusselsmuseumsnocturnes.be/fr/ Ed. resp. : A. Medhoune - 50, av. F.D. Roosevelt (CP 166/02) - 1050 Bruxelles – graphisme : Geluck-Suykens, d’Andrimont - Jules Bordet (1870-1961) vers 1920 © Institut Pasteur, Musée Pasteur Musée Pasteur, © Institut 1920 vers (1870-1961) Bordet - Jules d’Andrimont : Geluck-Suykens, – graphisme - 1050 Bruxelles 166/02) (CP Roosevelt F.D. av. - 50, : A. Medhoune resp. Ed. Cent ans d’un prix Nobel Première partie : une vie Jules Bordet, un pastorien à l’ULB De la naissance au diplôme (1870-1892) Une curiosité en éveil, un esprit qui se prépare Voyage au coeur de l’immunité Dans les champs de l’observation, le hasard ne favorise que Quand on parle d’immunité, c’est [de] l’obstacle opposé à l’infection les esprits préparés qu’il s’agit... Louis Pasteur, Discours de Douai, 7 décembre 1858 Jules Bordet, 1920 Jules Bordet est né à Soignies le 18 juin 1870. Dès son plus jeune âge, il s’intéresse à la science, comme en témoignent ses cahiers d’écolier Étudiant à l’ULB, chercheur à l’Institut Pasteur de Paris, puis professeur à et l’installation d’un petit laboratoire de chimie dans la maison familiale.